Hussman Strategic Advisors Inc. Reduces Stock Holdings in Travere Therapeutics, Inc. $TVTX

Hussman Strategic Advisors Inc. trimmed its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 75.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 42,000 shares of the company’s stock after selling 126,000 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in Travere Therapeutics were worth $1,004,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Emerald Advisers LLC lifted its stake in shares of Travere Therapeutics by 2.6% during the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock valued at $51,308,000 after buying an additional 55,407 shares in the last quarter. Capital Fund Management S.A. purchased a new position in Travere Therapeutics in the 2nd quarter valued at approximately $1,501,000. Squarepoint Ops LLC raised its holdings in Travere Therapeutics by 98.7% during the 2nd quarter. Squarepoint Ops LLC now owns 479,394 shares of the company’s stock valued at $7,095,000 after acquiring an additional 238,070 shares during the period. Voya Investment Management LLC raised its holdings in Travere Therapeutics by 16.2% during the 3rd quarter. Voya Investment Management LLC now owns 194,854 shares of the company’s stock valued at $4,657,000 after acquiring an additional 27,133 shares during the period. Finally, Y Intercept Hong Kong Ltd lifted its position in shares of Travere Therapeutics by 343.7% during the second quarter. Y Intercept Hong Kong Ltd now owns 68,000 shares of the company’s stock worth $1,006,000 after acquiring an additional 52,675 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TVTX shares. Wall Street Zen upgraded Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. HC Wainwright restated a “buy” rating and issued a $47.00 target price on shares of Travere Therapeutics in a research note on Friday, November 28th. Guggenheim reaffirmed a “buy” rating and set a $49.00 target price on shares of Travere Therapeutics in a report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Finally, Citigroup increased their price target on shares of Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.86.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $30.28 on Thursday. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of -28.57, a PEG ratio of 0.99 and a beta of 0.85. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23. The business has a 50-day simple moving average of $34.35 and a 200 day simple moving average of $27.24. Travere Therapeutics, Inc. has a 52 week low of $12.91 and a 52 week high of $42.13.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The firm had revenue of $164.86 million for the quarter, compared to analysts’ expectations of $106.09 million. During the same quarter last year, the firm posted ($0.70) EPS. The company’s revenue was up 162.1% compared to the same quarter last year. On average, research analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider William E. Rote sold 60,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $40.10, for a total value of $2,406,000.00. Following the sale, the insider directly owned 101,443 shares of the company’s stock, valued at $4,067,864.30. This trade represents a 37.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Eric M. Dube sold 51,865 shares of Travere Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $30.10, for a total transaction of $1,561,136.50. Following the sale, the chief executive officer owned 419,173 shares of the company’s stock, valued at approximately $12,617,107.30. The trade was a 11.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 270,564 shares of company stock valued at $9,650,917 in the last 90 days. 4.06% of the stock is owned by company insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.